Dr. Castellino is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5461 Meridian Mark Rd
Ste 400
Atlanta, GA 30342Phone+1 404-785-1112Fax+1 404-785-3600
Education & Training
- Wake Forest UniversityMSc, Health Outcomes, 2005 - 2008
- Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1995 - 1998
- Duke University HospitalResidency, Pediatrics, 1994 - 1995
- Boston Children’s Hospital/Boston Medical CenterInternship, Pediatrics, 1992 - 1994
- Duke University School of MedicineClass of 1992
- Mount Holyoke CollegeBA, Biochemistry, Magna Cum Laude, 1984 - 1988
Certifications & Licensure
- GA State Medical License 2015 - 2026
- NC State Medical License 1994 - 2025
- TN State Medical License 1998 - 2005
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Clinician Investigator Award Wake Forest School of Medicine, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Join now to see all
Clinical Trials
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
- Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsA review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations.Julie Blatt, Thomas W. McLean, Sharon M. Castellino, Craig N. Burkhart
Pharmacology & Therapeutics. 2013-09-01 - 323 citationsGermline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic typeLeora Witkowski, Jian Carrot-Zhang, Steffen Albrecht, Somayyeh Fahiminiya, Nancy Hamel
Nature Genetics. 2014-05-01 - 115 citationsLate Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group ReportEric J. Chow, Lynnette Anderson, K. Scott Baker, Smita Bhatia, Gregory M.T. Guilcher
Biology of Blood and Marrow Transplantation. 2016-05-01
Journal Articles
- Incidence and Outcomes of Lymphoid Malignancies in Adolescent and Young Adult Patients in the United StatesSharon Castellino, Frank G Keller, Christopher R Flowers, British Journal of Haematology
- Occult GI Bleeding in a 1 yo Pediatric Cancer SurvivorGrimes K, Kratzer T, Russo K, Bourland D, Castellino SM, J Pediatr Gastroenerol Nutr., 1/1/2014
- Hepato-Biliary Late Effects in Survivors of Childhood and Adolescent Cancer - A Report from the Children’s Oncology GroupCastellino SM, Muir A, Shah A, Shope S, McMullen K, Ruble K, Barber A, Davidoff A, Hudson MM, Pediatr Blood Cancer, 1/1/2010
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Intensive therapy free survival (ITFS) for early-stage Hodgkin lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy al...Keller F, Castellino SM et al., Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium, Berlin, Germany, 1/7/2014
- Longitudinal Evaluation of Health Status in Aging Pediatric Hodgkin Lymphoma Survivors: Report from the Childhood Cancer Survivor Study.Effinger K, Leisenring W, Oeffinger KC, Hudson MM, Ness KK, Marina N, Castellino SM Stovall M, Armstrong GT, Robison LL, Sainani K, Whittemore AS, International Symposium Pediatric HL, Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium, Berlin, Germany, 1/7/2014
- Outcomes and Patterns of Failure in Children/Adolescents with low risk Hodgkin Lymphoma (HL) who are FDG-PET (PET3) positive after AVPC therapy International Symposium...Castellino SM et. al., Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium, Berlin, Germany, 1/7/2014
- Join now to see all
Lectures
- Performance of FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric hodgkin lymphoma (HL) patients.2019 ASCO Annual Meeting - 6/1/2019
- Proof-of-Paradigm of Cost-Effectiveness Analysis Within a Therapeutic Clinical Trial2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Immune Modulation in Pediatric Lymphoma2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Press Mentions
- Immunotherapy Breakthrough: 92% Survival for Hodgkin Lymphoma PatientsOctober 18th, 2024
- Immunotherapy Extends Survival in Advanced Hodgkin LymphomaOctober 18th, 2024
- Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin LymphomaOctober 17th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: